A validation study of PHQ-9 suicide item with the Columbia Suicide Severity Rating Scale in outpatients with mood disorders at National Network of Depression Centers.

Autor: Chung TH; Department of Healthcare Transformation Initiatives, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA. Electronic address: Tong.Han.Chung@uth.tmc.edu., Hanley K; Department of Healthcare Transformation Initiatives, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA., Le YC; Department of Healthcare Transformation Initiatives, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA., Merchant A; Department of Healthcare Transformation Initiatives, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA., Nascimento F; Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA., De Figueiredo JM; Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA., Wilcox HC; Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Mental Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA., Coryell WH; Department of Psychiatry, Carver College of Medicine, University of Iowa, Iowa City, IA, USA., Soares JC; Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA., Selvaraj S; Department of Psychiatry and Behavioral Sciences, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Jazyk: angličtina
Zdroj: Journal of affective disorders [J Affect Disord] 2023 Jan 01; Vol. 320, pp. 590-594. Date of Electronic Publication: 2022 Sep 29.
DOI: 10.1016/j.jad.2022.09.131
Abstrakt: Background: In the United States, suicide is one of the serious public health problems and a major cause of death. Several researchers and clinical settings use the patient health questionnaires (PHQ-9) to gauge depression and psychological distress among adults and to predict suicide and death. This study aimed to assess the sensitivity, specificity, and predictive potential of suicide Q9 of the PHQ-9 compared to the Columbia-suicide severity rating scale (C-SSRS).
Methods: Adults aged 19 or older, identified with a primary mood disorder diagnosis during their initial clinic visit between 2012 and 2020 from the National Network of Depression Centers, were included in the study. The accuracy of the PHQ-9 suicide item was compared with the gold standard, the C-SSRS.
Results: Out of 2677 study participants, 31.6 % (n = 846) and 11.65 % (n = 312) had positive responses to the PHQ-9 suicide item and C-SSRS response, respectively. The sensitivity of the PHQ-9 compared to the C-SSR was 74.7 % (95%CI: 69.6 %-79.2 %), specificity 74.1 % (95%CI: 72.3 %-75.8 %), positive predictive value 27.5 % (95%CI: 24.6 %-30.6 %), and negative predictive value 95.7 % (95%CI: 94.7 %-96.5 %). The secondary analysis results showed better validity results of the PHQ-9 suicide item when compared to the suicide ideation item of the C-SSRS.
Limitations: This study is among mood disorder patients so additional research would be necessary among populations with different conditions.
Conclusion: For initial suicide screening, the PHQ-9 suicide item would over identify patients as at risk for suicide and the C-SSRS should be used mood disorder clinics to identify suicide risk.
Competing Interests: Declaration of competing interest Dr. Selvaraj has received speaking honoraria from Global Medical Education and honoraria from British Medical Journal Publishing Group and study or sub-investigator for clinical trials by Flow neuroscience, COMPASS Pathways Limited, Janssen, Relmada, and Liva Nova. J.C·S has received grants/research support from BMS, Forrest, J&J, Merck, Compass pathways, Relmada, Liva Nova, Stanley Medical Research Institute, NIH, and has been a speaker for Pfizer and Abbott. All other authors do not report any financial conflicts of interest.
(Copyright © 2022 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: